BFG
TGTX icon

Bleakley Financial Group’s TG Therapeutics TGTX Stock Holding History

Bleakley Financial Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$666K Buy
12,122
+494
+4% +$20.2K 0.01% 737
2026
Q1 		$386K Buy
+11,628
New +$347K 0.01% 684
2025
Q1 		– Sell
-8,140
Closed -$245K – 948
2024
Q4 		$245K Buy
+8,140
New +$234K 0.01% 878

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Bleakley Financial Group's TGTX Position: Q2 2026 in Review

Bleakley Financial Group increased its TG Therapeutics (TGTX) stake by 4.2% in Q2 2026, buying an estimated $20.2K and bringing the position to 12,122 shares worth $666K. The position accounts for 0.01% of the portfolio, ranked #737.

Bleakley Financial Group first reported a position in TGTX in Q4 2024 and has held it in 3 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Bleakley Financial Group held 12,122 shares of TG Therapeutics worth $666K as of Q2 2026.
  • Bleakley Financial Group bought 494 TG Therapeutics shares in Q2 2026, an estimated $20.2K.
  • TG Therapeutics made up 0.01% of Bleakley Financial Group's portfolio in Q2 2026, its #737 holding.
  • Bleakley Financial Group first reported a position in TG Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Bleakley Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.